Should patients with a strong family history of pancreatic cancer be screened on a periodic basis for cancer of the pancreas?

Pancreas

Volumn 38, Issue 5, 2009, Pages

  Canto, Marcia Irene ^a   Levy, Michael J ^b   Steinberg, William M ^c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Mayo Clinic   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN E; CYCLIN D2; GEMCITABINE; PROTEIN P16; TELOMERASE; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FAMILIAL CANCER; FAMILY HISTORY; GENETIC SCREENING; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LABORATORY TEST; MUCINOUS CARCINOMA; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS JUICE; PATIENT COMPLIANCE; PATIENT SELECTION; PERIODIC MEDICAL EXAMINATION; PRECANCER; PRIORITY JOURNAL; RELATIVE;

FAMILY HEALTH; HUMANS; MASS SCREENING; PANCREATIC NEOPLASMS;

EID: 67651089722     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181a86b2c     Document Type: Note

References (83)

1. Hart AR, Kennedy H, Harvey I. Pancreatic cancer: a review of the evidence on causation. Clin Gastroenterol Hepatol. 2008;6:275-282. (Pubitemid 351318383)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
3. Furukawa H, Okada S, Saisho H, et al. Clinicopathologic features of small pancreatic adenocarcinoma. A collective study. Cancer. 1996;78:986-990.
4. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 Patients. Ann Surg. 1995;221:721-731; discussion 731-733.
5. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496-3502.
6. Cleary SP, Gryfe R, Guindi M, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg. 2004;198:722-731. (Pubitemid 38542900)
7. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319: 525-532.
8. Howes N, Greenhalf W, Neoptolemos J. Screening for early pancreatic ductal adenocarcinoma in hereditary pancreatitis. Med Clin North Am. 2000;84:719-738. (Pubitemid 30346166)
9. Ulrich CD. Pancreatic cancer in hereditary pancreatitis: consensus guidelines for prevention, screening and treatment. Pancreatology. 2001;1:416-422.
10. Lowenfels AB, Maisonneuve P, Whitcomb DC. Risk factors for cancer in hereditary pancreatitis. International Hereditary Pancreatitis Study Group. Med Clin North Am. 2000;84:565-573.
11. Giardiello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med. 1987; 316:1511-1514. (Pubitemid 17076235)
12. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119:1447-1453.
13. Vasen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000;87:809-811.
14. Lynch HT, Fusaro RM, Lynch JF, et al. Pancreatic cancer and the FAMMM syndrome. Fam Cancer. 2008;7:103-112.
15. American Gastroenterological Association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology. 1999;117:1463-1484.
16. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005;42:711-719.
17. Pal T, Flanders T, Mitchell-Lehman M, et al. Genetic implications of double primary cancers of the colorectum and endometrium. J Med Genet. 1998;35:978-984. (Pubitemid 28534668)
18. Tersmette AC, Petersen GM, Offerhaus GJ, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res. 2001;7:738-744. (Pubitemid 32708001)
19. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004; 64:2634-2638. (Pubitemid 38523922)
20. Klein AP, Beaty TH, Bailey-Wilson JE, et al. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol. 2002;23:133-149.
21. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003;95: 214-221. (Pubitemid 36240634)
22. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 2002; 62:3789-3793. (Pubitemid 34728862)
23. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:342-346. (Pubitemid 46383356)
24. Pogue-Geile KL, Chen R, Bronner MP, et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med. 2006;3:e516. (Pubitemid 46026443)
25. Klein AP, de Andrade M, Hruban RH, et al. Linkage analysis of chromosome 4 in families with familial pancreatic cancer. Cancer Biol Ther. 2007;6:320-323. (Pubitemid 47328296)
26. Salaria SN, Illei P, Sharma R, et al. Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells. Cancer Biol Ther. 2007;6:324-328. (Pubitemid 47328297)
27. Zogopoulos G, Rothenmund H, Eppel A, et al. The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Hum Genet. 2007;121:635-637. (Pubitemid 46706075)
28. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 1997;89:442-446.
29. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12:3209-3215. (Pubitemid 43837371)
30. Goldstein AM, Chan M, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006;66:9818-9828. (Pubitemid 44672032)
31. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94:1365-1372. (Pubitemid 35154141)
32. Lynch HT, Deters CA, Snyder CL, et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet. 2005;158:119-125.
33. Johannsson O, Ostermeyer EA, Hakansson S, et al. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet. 1996;58:441-450. (Pubitemid 26062474)
34. Del Chiaro M, Zerbi A, Falconi M, et al. Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma. Pancreatology. 2007;7:459-469. (Pubitemid 47587625)
35. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med. 2004;1:e65. (Pubitemid 40418886)
36. Rulyak SJ, Lowenfels AB, Maisonneuve P, et al. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology. 2003;124:1292-1299. (Pubitemid 36531804)
37. Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir. 2004;59:99-111.
38. Michaud DS, Giovannucci E, Willett WC, et al. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA. 2001;286:921-929. (Pubitemid 33010338)
39. Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129:504-511. (Pubitemid 41096638)
40. Vasen HF, Mecklin JP, Khan PM, et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34:424-425.
41. Giardiello FM, Offerhaus GJ, Lee DH, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut. 1993;34:1394-1396. (Pubitemid 23293626)
42. Lynch HT, Lynch JF. 25 Years of HNPCC. Anticancer Res. 1994;14:1617-1624.
43. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006;4:766-781; quiz 665. (Pubitemid 43825802)
44. Kurtz RC, Simon J, Ludwig E, et al. A pancreatic cancer screening program for familial high-risk individuals [abstract]. Gastroenterology. 2007;132:A-199.
45. Poley J, Kluijt I, Gouma D, et al. Endoscopic ultrasonography is a valuable tool with high yield in screening of patients at high-risk for pancreatic cancer. Gastroenterology. 2008:A-110.
46. Maitra A, Fukushima N, Takaori K, et al. Precursors to invasive pancreatic cancer. Adv Anat Pathol. 2005;12:81-91.
47. Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28:977-987. (Pubitemid 38971421)
48. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969-2972.
49. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000;60:2002-2006. (Pubitemid 30207663)
50. Tanaka M. International consensus guidelines for the management of IPMN and MCN of the pancreas. Nippon Shokakibyo Gakkai Zasshi. 2007;104:1338-1343.
51. Kawamoto S, Horton KM, Lawler LP, et al. Intraductal papillary mucinous neoplasm of the pancreas: can benign lesions be differentiated from malignant lesions with multidetector CT? Radiographics. 2005;25:1451-1468; discussion 1468-1470.
52. Wiesenauer CA, Schmidt CM, Cummings OW, et al. Preoperative predictors of malignancy in pancreatic intraductal papillary mucinous neoplasms. Arch Surg. 2003;138:610-617; discussion 617-618.
53. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2:606-621. (Pubitemid 38834045)
54. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001;25:579-586. (Pubitemid 32423354)
55. Canto M, Goggins M, Schulick R, et al. The phenotype of familial pancreatic neoplasia. Gastroenterology. 2008;134:A-45.
56. Canto M, Schulick R, Goggins M, et al. Preoperative detection of familial pancreatic neoplasms by endoscopic ultrasonography(EUS), multidetector computed tomography (CT), and/or magnetic resonance cholangiopancreatography (MRCP). Gastrointest Endosc. 2008;65:AB225.
57. Brentnall TA. Cancer surveillance of patients from familial pancreatic cancer kindreds. Med Clin North Am. 2000;84:707-718. (Pubitemid 30346165)
58. Brentnall TA, Bronner MP, Byrd DR, et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999;131:247-255. (Pubitemid 29383653)
59. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17-32.
60. Brune K, Abe T, Canto M, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006;30:1067-1076. (Pubitemid 44299338)
61. Sahai AV, Zimmerman M, Aabakken L, et al. Prospective assessment of the ability of endoscopic ultrasound to diagnose, exclude, or establish the severity of chronic pancreatitis found by endoscopic retrograde cholangiopancreatography. Gastrointest Endosc. 1998;48:18-25. (Pubitemid 28337423)
62. Wiersema MJ, Hawes RH, Lehman GA, et al. Prospective evaluation of endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in patients with chronic abdominal pain of suspected pancreatic origin. Endoscopy. 1993;25:555-564.
63. Meckler KA, Brentnall TA, Haggitt RC, et al. Familial fibrocystic pancreatic atrophy with endocrine cell hyperplasia and pancreatic carcinoma. Am J Surg Pathol. 2001;25:1047-1053. (Pubitemid 32685902)
64. Topazian M, Enders F, Kimmey M, et al. Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. Gastrointest Endosc. 2007;66:62-67. (Pubitemid 46970752)
65. Kimmey MB, Bronner MP, Byrd DR, et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc. 2002;56:S82-S86.
66. Vitone LJ, Greenhalf W, Howes NR, et al. Hereditary pancreatitis and secondary screening for early pancreatic cancer. Rocz Akad Med Bialymst. 2005;50:73-84. (Pubitemid 30346166)
67. Ogawa Y, Tanaka M, Inoue K, et al. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer. 2002;94:2344-2349. (Pubitemid 34457114)
68. Lemoine NR. Molecular advances in pancreatic cancer. Digestion. 1997;58:550-556.
69. Uno K, Azuma T, Nakajima M, et al. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol. 2000;15: 1333-1338.
70. Matsubayashi H, Canto M, Sato N, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res. 2006;66:1208-1217. (Pubitemid 43165992)
71. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am. 2002;16:37-52.
72. Wang W, Chen S, Brune KA, et al. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol. 2007;25:1417-1422. (Pubitemid 46706891)
73. Canto M. Screening and surveillance approaches in familial pancreatic cancer. Gastrointest Endosc Clin N Am. 2008;18:535-553.
74. Charpentier KP, Brentnall TA, Bronner MP, et al. A new indication for pancreas transplantation: high grade pancreatic dysplasia. Clin Transplant. 2004;18:105-107.
75. Ujiki MB, Talamonti MS. Guidelines for the surgical management of pancreatic adenocarcinoma. Semin Oncol. 2007;34:311-320. (Pubitemid 47176619)
76. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database [see comment]. J Am Coll Surg. 1999;189:1-7.
77. Nitecki SS, Sarr MG, Colby TV, et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 1995;221:59-66.
78. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.[see comment]. J Gastrointest Surg. 2000;4:567-579.
79. Canto MI. Strategies for screening for pancreatic adenocarcinoma in high-risk patients. Semin Oncol. 2007;34:295-302. (Pubitemid 47176623)
80. Rulyak SJ, Brentnall TA, Lynch HT, et al. Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer. 2003;98:798-804.
81. Ariyama J, Suyama M, Satoh K, et al. Endoscopic ultrasound and intraductal ultrasound in the diagnosis of small pancreatic tumors. Abdom Imaging. 1998;23:380-386. (Pubitemid 28304755)
82. Kimmey MB, Bronner MP, Byrd DR, et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc. 2002; 56:S82-S86.
83. Klein A, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004; 64:2634-2638. (Pubitemid 38523922)